medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 1

<< Back

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (1)

Second primary neoplasms in patients with chronic lymphocytic leukemia

Concepción FY, Quintero SY, Borges MYC

Language: Spanish
References: 15
Page: 1-5
PDF size: 264.35 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. DOI: https://3322/caac.21442

  2. Surveillance, Epidemiology, and End Results Program (SEER) Program Populations (1969-2016). National Cancer Institute, Surveillance Research Program. 2020 [acceso 25/07/2021]; Disponible en: Disponible en: https://seer.cancer.gov/popdata

  3. da Cunha-Bang C, Simonsen J, Rostgaard K, Geisler C, Hjalgrim H, Niemann CU et al. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer J. 2016 Nov 11;6(11):e499. DOI: https://10.1038/bcj.2016.105

  4. Concepción Fernández Y, Quintero Sierra Y, Romero González A. Actualidades terapéuticas en leucemia linfoide crónica. Rev Cubana Hematol Inmunol Hemoter. 2021 Sep [acceso 07/10/2021];37(3):e1344. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892021000300003&lng=es .

  5. Braakhnis BJ, Tabor MP, Leemans CR, van der Waal J, Snow GB, Brakarhoff RH. Second primary tumours and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 2002;24(2):198-206.

  6. Turcotte LM, Liu Q, Yasui Y, Arnold MA, Hammond S, Howell RM et al. Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970-2015. JAMA. 2017 Feb;317(8):814-24. DOI: https://10.1001/jama.2017.0693

  7. Bond DA, Huang Y, Fisher JL, Ruppert AS, Owen DH, Bertino EM et al. Second cancer incidence in chronic lymphocytic leukemia (cll) patients receiving BTK in hibitors. Leukemia. 2020 Dec;34(12):3197-3205. DOI: https://10.1038/s41375-020-0987-6

  8. Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T et al. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019 Sep;9(10):75 DOI: https://10.1038/s41408-019-0237-1

  9. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB et al. Cancer survivorship genetic susceptibility and second primary cancers: research strategies and recommendations. J. Natl Cancer Inst. 2006;98(1):15-25.

  10. Brewer JD, Shanafelt TD, Call TG, Cerhan JR, Roenigk RK, Weaver AL et al. Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chroic Lymphocytic Leukemia. Int J Dermatol. 2015 Aug;54(8):e287-93 DOI: https://10.1111/ijd.12564

  11. Tsimberidou AM, Wen S, McLaughlin P, O Brien S, Wierda WG, Lerner S, et al. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J. Clin. Oncol.2009;27(6),904-10.

  12. Swaika A, Frank RD, Yang D, Finn LE, Jiang L, Advani P, et al. Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes. Cancer Med. 2018 Feb;7(2):499-507. DOI: https://10.1002/cam4.1266

  13. Benjamini, O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk. Lymphoma. 2015;56(6):1643-50.

  14. Solomon BM, Chaffee MS, Moreira J, Schwager SM, Cerhan JR, Call TG, et al. Risk of non-hematologic cancer in individuals with highcount monoclonal B-cell lymphocytosis. Leukemia. 2016 Feb;30(2):331-6. DOI: https://10.1038/leu.2015.235

  15. Burger JA, O’Brien S. Evolution of CLL treatment from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018 Aug;15(8):510-527. DOI: https://10.1038/s41571-018-0037-8




2020     |     www.medigraphic.com